Targeting HIF2α in Clear-Cell Renal Cell Carcinoma

Christopher J Ricketts; Daniel R Crooks; W Marston Linehan

doi:10.1016/j.ccell.2016.09.016

Targeting HIF2α in Clear-Cell Renal Cell Carcinoma

Cancer Cell. 2016 Oct 10;30(4):515-517. doi: 10.1016/j.ccell.2016.09.016.

Authors

Christopher J Ricketts¹, Daniel R Crooks¹, W Marston Linehan²

Affiliations

¹ Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1107, USA.
² Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1107, USA. Electronic address: [email protected].

PMID: 27728802
DOI: 10.1016/j.ccell.2016.09.016

Abstract

In two recent studies, the HIF2α antagonist, PT2399, decreased HIF2α-dependent transcription and tumor growth in selected VHL-deficient clear-cell renal cell carcinoma (ccRCC) models. These studies validate HIF2α as a therapeutic target in ccRCC, reveal variable sensitivity to HIF2α antagonism, and provide the foundation for predictive biomarker-driven clinical trials.

Published by Elsevier Inc.

Publication types

Comment

MeSH terms

Animals
Basic Helix-Loop-Helix Transcription Factors / antagonists & inhibitors*
Basic Helix-Loop-Helix Transcription Factors / genetics*
Carcinoma, Renal Cell / drug therapy*
Carcinoma, Renal Cell / genetics
Humans
Indans / pharmacology*
Kidney Neoplasms / drug therapy*
Mice
Mice, Nude
Molecular Targeted Therapy
Sulfones / pharmacology*

Substances

Basic Helix-Loop-Helix Transcription Factors
Indans
PT2399
Sulfones
endothelial PAS domain-containing protein 1